- Home
- CROX vs RGEN Comparison
CROX vs RGEN Comparison
Compare CROX & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- RGEN
- Stock Information
- Founded
- CROX 1999
- RGEN 1981
- Country
- CROX United States
- RGEN United States
- Employees
- CROX N/A
- RGEN N/A
- Industry
- CROX Shoe Manufacturing
- RGEN Medical/Dental Instruments
- Sector
- CROX Consumer Discretionary
- RGEN Health Care
- Exchange
- CROX Nasdaq
- RGEN Nasdaq
- Market Cap
- CROX 8.3B
- RGEN 7.6B
- IPO Year
- CROX 2006
- RGEN N/A
- Fundamental
- Price
- CROX $111.21
- RGEN $157.10
- Analyst Decision
- CROX Buy
- RGEN Buy
- Analyst Count
- CROX 15
- RGEN 12
- Target Price
- CROX $146.21
- RGEN $187.44
- AVG Volume (30 Days)
- CROX 1.3M
- RGEN 511.7K
- Earning Date
- CROX 10-29-2024
- RGEN 11-12-2024
- Dividend Yield
- CROX N/A
- RGEN N/A
- EPS Growth
- CROX 27.09
- RGEN N/A
- EPS
- CROX 13.79
- RGEN N/A
- Revenue
- CROX $4,072,432,000.00
- RGEN $633,513,000.00
- Revenue This Year
- CROX $4.94
- RGEN $2.23
- Revenue Next Year
- CROX $3.05
- RGEN $10.07
- P/E Ratio
- CROX $8.09
- RGEN N/A
- Revenue Growth
- CROX 3.17
- RGEN N/A
- 52 Week Low
- CROX $85.71
- RGEN $113.50
- 52 Week High
- CROX $165.32
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- CROX 52.07
- RGEN 60.44
- Support Level
- CROX $108.66
- RGEN $151.50
- Resistance Level
- CROX $113.10
- RGEN $161.24
- Average True Range (ATR)
- CROX 3.04
- RGEN 5.06
- MACD
- CROX 0.86
- RGEN 0.89
- Stochastic Oscillator
- CROX 73.08
- RGEN 82.16
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include the Americas, Asia Pacific, and EMEA.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.